

# SWANSON & BRATSCHUN, L.L.C.

1745 SHEA CENTER DRIVE  
SUITE 330  
HIGHLANDS RANCH, COLORADO 80129  
TELEPHONE (303) 268-0066  
FACSIMILE (303) 268-0065  
e-Mail: firm@sbiplaw.com

## FACSIMILE COVER PAGE

TO: Examiner Yelena Gakh  
COMPANY: USPTO Group Art Unit 1743  
FACSIMILE #: (703) 746-7165  
FROM: Darla Yoerg (Barry J. Swanson)  
DATE: October 27, 2003

Number of pages, including cover page 10 Faxed \_\_\_\_\_



Please call Elizabeth at (303) 258-0066 if you do not receive all pages or have trouble receiving this transmission.

THIS TRANSMISSION AND THE ACCOMPANYING DOCUMENTS MAY CONTAIN CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE RECIPIENT NAMED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT NAMED ABOVE, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE OR ACTION TAKEN BASED UPON THE CONTENT OF THIS TRANSMISSION IS PROHIBITED. IF YOU HAVE RECEIVED THIS INFORMATION IN ERROR, PLEASE NOTIFY OUR OFFICE IMMEDIATELY AND MAIL THIS TRANSMISSION TO OUR OFFICE.

---

Examiner Gakh,

Per your phone message, please find following the missing IDS, date-stamped postcard receipt showing receipt in the PTO on February 27, 2002, and copies of the references cited on form PTO-1449.

Attorney Docket: SURR.85

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	SINGH ET AL.	}	EXAMINER:
SERIAL NO.:	10/044,310		ART UNIT:
FILED:	JANUARY 11, 2001		CONFIRMATION NO:
TITLE:	MASS SPECTROMETRY OF PROSTAGLANDINS		

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

37 CFR 1.8

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231 on 11/3/03

Signature:

Name: Tasha L. Cove

Received from < > at 10/27/03 3:44:00 PM [Eastern Standard Time]

BEST AVAILABLE COPY

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,



Darla G. Yoerg, #48,053  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
Telephone: (303) 268-0066  
Facsimile: (303) 268-0065

cc: William Leschensky  
S:\CLIENT FOLDERS\SURROMED\85\IDS.DOC

**DATE:** February 11, 2002  
**APPLICANT:** SINGH *ET AL.*  
**SERIAL NO.:** 10/044,310  
**FOR:** MASS SPECTROMETRY OF PROSTAGLANDINS

**RECEIPT IS HEREBY ACKNOWLEDGED OF:**  
Supplemental Information Disclosure Statement: 2 pages  
PTO Form 1449: 1 page  
Other Documents: 6



Docket No. SURR.85

BEST AVAILABLE COPY

# SWANSON & BRATSCHUN, L.L.C.

1745 SHEA CENTER DRIVE  
SUITE 330  
HIGHLANDS RANCH, COLORADO 80129  
TELEPHONE (303) 268-0066  
FACSIMILE (303) 268-0065  
e-Mail: firm@sbiplaw.com

## FACSIMILE COVER PAGE

TO: Examiner Yclena Gakh  
COMPANY: USPTO Group Art Unit 1743  
FACSIMILE #: (703) 746-7165  
FROM: Barry J. Swanson  
DATE: October 27, 2003

Number of pages, including cover page 16 Faxed \_\_\_\_\_

Please call Elizabeth at (303) 268-0066 if you do not receive all pages or have trouble receiving this transmission.

THIS TRANSMISSION AND THE ACCOMPANYING DOCUMENTS MAY CONTAIN CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE RECIPIENT NAMED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT NAMED ABOVE, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE OR ACTION TAKEN BASED UPON THE CONTENT OF THIS TRANSMISSION IS PROHIBITED. IF YOU HAVE RECEIVED THIS INFORMATION IN ERROR, PLEASE NOTIFY OUR OFFICE IMMEDIATELY AND MAIL THIS TRANSMISSION TO OUR OFFICE.

---

Examiner Gakh,

Following are the FIVE IDS's that have been submitted in this case. We mailed the second one on 2/13/02, but PAIR has it as 6/2/02. The others match up pretty closely. Once you have had a chance to review this material, please call me to discuss.

Express Mail Label N . EV001126311US  
Docket No. SURR.85

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: SINGH ET AL.  
SERIAL NO.:  
FILED: JANUARY 11, 2002  
TITLE: MASS SPECTROMETRY OF  
PROSTAGLANDINS

EXAMINER:  
ART UNIT:  
CONFIRMATION NO:

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

#1 - filed with application  
1/11/2002

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.


No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of

interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: June 11, 2002



Barry V. Swanson, #33,215  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
Telephone: (303) 268-0066  
Facsimile: (303) 268-0065

S:\CLIENT FOLDERS\SURROMED\85\US\UDS WITHOUT OPTIONS.DOC

21

BEST AVAILABLE COPY

<b>FORM PTO-1449</b> <b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b> List of Information Cited by Applicant Page 1 of 1	<b>ATTY. DOCKET NO.</b> SURR.85	<b>SERIAL NO.</b>
	<b>APPLICANT</b> SINGH ET AL	
	<b>FILING DATE</b> JANUARY 11, 2002	<b>GROUP</b>

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AR						
	AS						
	AT						
	AU						
	AV						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AW	Gillespie et al. (1990) J Am Soc Mass Spectrom 1, 389-396, "Differences in the Low-Energy Collision-Activated Dissociation of Carboxylate Anions from Structurally Similar Prostaglandins: E2, F2 $\alpha$ , D2, and DHKF2 $\alpha$ "
	AX	Li et al., (11/1999) Proc. Natl. Acad. Sci. 96:13381-13386, "Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F2-isoprostanes in human urine."
	AY	
	AZ	
	AAA	
	AAB	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MP&P 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



Attorney Docket: SURR.85

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: SINGH ET AL.  
SERIAL NO.: 10/044,310  
FILED: JANUARY 11, 2001  
TITLE: MASS SPECTROMETRY OF  
PROSTAGLANDINS

EXAMINER:  
ART UNIT:  
CONFIRMATION NO:

4

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

#2 - 2/13/02

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

37 CFR 1.8  
CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231 on 2/13/02


Signature: Tasha L. Cove  
Name: Tasha L. Cove

Received from &lt; &gt; at 10/27/03 1:17:25 PM [Eastern Standard Time]

BEST AVAILABLE COPY

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,



Darla G. Yoerg, #48,053  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
Telephone: (303) 268-0066  
Facsimile: (303) 268-0065

cc: William Leschensky  
S:\CLIENT FOLDERS\SURROMED\85\IDS.DOC

BEST AVAILABLE COPY

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  List of Information Cited by Applicant Page 1 of 1	<b>ATTY. DOCKET NO.</b> SURR.85	<b>SERIAL NO.</b> 10/044,310
	<b>APPLICANT</b> SINGH ET AL.	
	<b>FILING DATE</b> JANUARY 11, 2001	<b>GROUP</b>

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AR						
	AS						
	AT						
	AU						
	AV						
	AW						
	AX						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AY	Eling et al., (1982) Methods in Enzymology 86:511-517	
AZ	Roberts & Morrow, (1997) Biochim. Biophys. Acta. 1345:121-135	
AAA	Tsikas et al., (1998) J. Chromatogr. B 717:201-245	
AAH	Tsikas et al., (1998) J. Chromatogr. B 716:7-17	
AAC	Wang et al., (1995) J. Pharmacol. Exp. Ther. 275:94-100	
AAD	Whorton et al., (1979) J. Chromatogr. 163:64-71	
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

\\SWANSONBRATS01\COMPANY\Client Folders\Surremed\85\JDS.doc

Received from &lt; &gt; at 10/27/03 1:17:25 PM (Eastern Standard Time)

BEST AVAILABLE COPY

Attorney Docket: SURR.85

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	SINGH ET AL.	}	EXAMINER:	
SERIAL NO.:	10/044,310		ART UNIT:	1743
FILED:	JANUARY 11, 2001		CONFIRMATION NO.:	
TITLE:	MASS SPECTROMETRY OF PROSTAGLANDINS			

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

37 CFR 1.8

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231 on 10/27/03

Signature:


Name: Tasha L. Cove

Received from &lt; &gt; at 10/27/03 1:17:25 PM [Eastern Standard Time]

BEST AVAILABLE COPY

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

  
\_\_\_\_\_  
Darla G. Yoerg, #48,053  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
Telephone: (303) 268-0066  
Facsimile: (303) 268-0065

8

cc: William Leschensky  
S:\CLIENT FOLDERS\SURROMED\85\SUPP IDS.DOC

BEST AVAILABLE COPY

<b>FORM PTO-1449</b> <b>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b> List of Information Cited by Applicant Page 1 of 1	<b>ATTY. DOCKET NO.</b> SURR.85	<b>SERIAL NO.</b> 10/044,310
	<b>APPLICANT</b> SINGH ET AL.	
	<b>FILING DATE</b> JANUARY 11, 2001	<b>GROUP</b> 1743

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA	5,122,670	06/1992	Mylchreest et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AR						
	AS						
	AT						
	AU						
	AV						
	AW						
	AX						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AY	Abian (1988) Biomed. Environ. Mass Spectrom. 16(1-12):215-219 Abstract	
AZ	Lawson et al. (1998) J. Biol. Chem. 273(45):29295-29301	
AAA	Kempen et al. (2001) Anal. Biochem. 297:183-201 Abstract	
AAB		
AAC		
AAD		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

S:\Client Folders\Surrem\85\Supp IDS.doc

Received from &lt; &gt; at 10/27/03 1:17:25 PM [Eastern Standard Time]

BEST AVAILABLE COPY

Attorney Docket: SURR.85

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: SINGH ET AL.  
SERIAL NO.: 10/044,310  
FILED: JANUARY 11, 2001  
TITLE: MASS SPECTROMETRY OF  
PROSTAGLANDINS

EXAMINER:  
ART UNIT:  
CONFIRMATION NO: 10

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

37 CFR 1.8  
CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231 on 9/12/02

Signature: *Yasha L. Cove*


Name: Yasha L. Cove

Received from &lt; &gt; at 10/27/03 1:17:25 PM [Eastern Standard Time]

BEST AVAILABLE COPY

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed parents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,



Darla G. Yoerg, #48,053  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
Telephone: (303) 268-0066  
Facsimile: (303) 268-0065

cc: William Leschensky  
SACLIENT FOLDERS\SURROMED\55SUPP 02IDS.DOC



<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</b>  List of Information Cited by Applicant Page 1 of 1	<b>ATTY. DOCKET NO.</b> SURR.85	<b>SERIAL NO.</b> 10/044,310
	<b>APPLICANT</b> SINGH ET AL.	
	<b>FILING DATE</b> JANUARY 11, 2001	<b>GROUP</b>

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AR						
	AS						
	AT						
	AU						
	AV						
	AW						
	AX						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AY	Abian et al. Biomedical and Environmental Mass Spectrometry, 16:215-219 (1988)
	AZ	
	AAA	
	AAB	
	AAC	
	AAD	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

S:\Client Folders\Surrounded\85\Supp 02\DS.doc

Received from &lt; &gt; at 10/27/03 1:17:25 PM [Eastern Standard Time]

BEST AVAILABLE COPY

Attorney Docket: SURR.85

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: SINGH ET AL.  
SERIAL NO.: 10/044,310  
FILED: JANUARY 11, 2001  
TITLE: MASS SPECTROMETRY OF  
PROSTAGLANDINS

EXAMINER:  
ART UNIT: 1743  
CONFIRMATION NO:

13

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

#5 12/11/02

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

37 CFR 1.8

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231 on 11-2-02

Signature: \_\_\_\_\_  
Name: Dehise Magoc

<b>FORM PTO-1449</b> <b>U.S. DEPARTMENT OF</b> <b>COMMERCE PATENT</b> <b>AND TRADEMARK</b> <b>OFFICE</b>  List of Information Cited by Applicant Page 1 of 1	<b>ATTY. DOCKET NO.</b> SURR.85	<b>SERIAL NO.</b> 10/044,310
	<b>APPLICANT</b> SINGH ET AL.	
	<b>FILING DATE</b> JANUARY 11, 2002	<b>GROUP</b> 1743

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB-CLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB-CLS	TRANS ?
	AM						
	AN						
	AO						
	AP						
	AQ						
	AR						
	AS						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AT	Pace-Asciak, et al. "Gas chromatographic-mass spectrometric profiling with negative-ion chemical ionization of prostaglandin and their 15-keto- 13,14-dihydro catabolites in rat blood", J. Chromatogr., 1984, v. 310 (2), pp. 233-42, Abstract	
AZ	Adachi et al., "Characterization of prostaglandin by LC/APCI-MS", Bunsenki Kagaku, 1994, 43 (3), pp. 189-94, Abstract	
AAA	Obata, et al., "Simultaneous quantitative analysis of prostaglandin by GC/MS for cell characterization", Nippon Iyo Masu Supekutoru Gakkai Koenshu, 1995, 20, pp. 89-92, Abstract	
AAB		
AAC		
AAD		
<b>EXAMINER</b> _____ <b>DATE CONSIDERED</b> _____ *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

S:\Client Folders\Surromed\85\Supp IDS 2.doc


Received from &lt; &gt; at 10/27/03 1:17:25 PM [Eastern Standard Time]

BEST AVAILABLE COPY

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

15

  
\_\_\_\_\_  
Darla G. Yoerg, #48,053/  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
Telephone: (303) 268-0066  
Facsimile: (303) 268-0065

cc: William Leschensky  
S:\CLIENT FOLDERS\SURROMED\85\SUPP IDS 2.DOC